• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Obstetrics

Quick Take: Neoadjuvant degarelix versus triptorelin in premenopausal patients who receive letrozole for locally advanced endocrine-responsive breast cancer: a randomized phase II trial

byAliya Ramjaun
January 3, 2019
in Obstetrics, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

RELATED REPORTS

Alternative Dose Regimens of Exemestane in Postmenopausal Women with Breast Cancer

Combination therapy with alisterib and fulvestrant may be clinically advantageous in the treatment of endocrine-resistant advanced breast cancer

Liver enzymes elevated at 6 months prior to breast cancer liver metastasis detection

Ovarian function suppression (OFS) is considered an important aspect of treatment in premenopausal women with advanced endocrine-responsive breast cancer. Degarelix is a gonadotropin-releasing hormone (GnRH) antagonist, which, when bound to GnRH receptors in the pituitary, results in a decreased secretion of gonadotropins. In men, this leads to a rapid decrease in the production of testosterone, and degarelix is approved in the treatment of prostate cancer. In premenopausal women, OFS may be achieved faster with degarelix than with GnRH analogs. The aim of this study was to compare the endocrine activity of triptorelin versus degarelix in premenopausal patients with breast cancer receiving letrozole as neoadjuvant endocrine therapy (NET). In this randomized controlled trial, 51 premenopausal women with stage cT2 to 4b, estrogen receptor and progesterone receptor greater than 50%, and human epidermal growth factor receptor 2-negative invasive breast cancer were randomized to receive triptorelin 3.75 mg (administered intramuscularly on day 1 of every cycle) or degarelix 240 mg (administered subcutaneously on day 1 of cycle 1, and then 80 mg on day 1 of cycles 2-6), both with letrozole 2.5 mg/day for six 28-day cycles. Surgery was performed 2-3 weeks after the last injections. Researchers found that the time to optimal OFS was significantly shorter in patients that received degarelix and letrozole, when compared to the control group (median 3 vs. 14 days, HR 3.05, 95% CI 1.65 to 5.65, p<0.001). OFS was also maintained during subsequent cycles for all patients that received degarelix and letrozole. Conversely, 15.4% of patients in the control group had suboptimal OFS after the first cycle. This study therefore shows that in premenopausal women receiving letrozole for NET, OFS is achieved more quickly and sustained more effectively with the use of degarelix as compared to triptorelin.

Click to read the study in JCO

Image: PD

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Breast Cancerdegarelixtriptorl
Previous Post

Quick Take: Risk of Depression and Anxiety in Adults With Cerebral Palsy

Next Post

Revisional surgeries common after bariatric surgery

RelatedReports

Adjuvant radiation decreases local recurrence in low-risk breast cancer
Oncology

Alternative Dose Regimens of Exemestane in Postmenopausal Women with Breast Cancer

March 27, 2023
Preoperative bilateral breast imaging may reduce contralateral cancer recurrence
Chronic Disease

Combination therapy with alisterib and fulvestrant may be clinically advantageous in the treatment of endocrine-resistant advanced breast cancer

March 12, 2023
Variability in interpretation of breast biopsy slides associated with low verification of atypia and ductal carcinoma in situ
Gastroenterology

Liver enzymes elevated at 6 months prior to breast cancer liver metastasis detection

March 8, 2023
#StudyGraphics: Adjuvant abemaciclib improves survival in patients  with hormone receptor-positive early breast cancer
StudyGraphics

#StudyGraphics: Adjuvant abemaciclib improves survival in patients with hormone receptor-positive early breast cancer

March 8, 2023
Next Post
Addressing non-obesity related barriers may improve bariatric surgery effectiveness

Revisional surgeries common after bariatric surgery

Greater prenatal alcohol exposure trajectories linked to impaired growth and neurodevelopment

Greater prenatal alcohol exposure trajectories linked to impaired growth and neurodevelopment

Quick Take: Effect of intranasal ketamine vs. fentanyl on pain reduction for extremity injuries in children: the PRIME randomized clinical trial

Quick Take: Effect of intranasal ketamine vs. fentanyl on pain reduction for extremity injuries in children: the PRIME randomized clinical trial

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • SAR-CoV-2 infection during pregnancy may lead to adverse neurodevelopmental outcomes in male offspring
  • Hyperfractionated radiotherapy reduces complication rates compared to standard fractionation for locally advanced nasopharyngeal carcinoma
  • Lebrikizumab effective in treating moderate-to-severe atopic dermatitis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options